Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Definitions

• a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy.
• the pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD-1 and a RAF inhibitor.
• a method for use in the prevention, delay of progression or treatment of cancer in a subject comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.
• Mitogen-activated protein kinase (MAPK) signaling pathway which consists of RAS-RAF- MEK-ERK kinase cascade is one of the critical signal transduction pathways in regulating diverse cellular activities, such as cell survival, growth, differentiation and proliferation. Genetic aberrations that lead to constitutive activation of the MAPK pathway are commonly observed in human cancers. Oncogenic B-Raf mutations, with V600E mutation accounting for at least 90%, have been detected in a variety of human malignancies. Inhibitors that selectively target mutated B- Raf such as vemurafenib and dabrafenib have achieved high response rate and been approved by FDA in treating melanoma patients harboring B-Raf V600E .
• B-Raf- targeting therapies could increase antigen expression, decrease immune suppressive factors in tumor microenvironment, and improve homing of T effector cells to the tumors.
• selective B-Raf inhibitors were suggested to possess immunosensitization properties and could be used in combination with immunotherapies to achieve more durable disease control/response in treating cancer.
• PD-1 Programmed Death 1 protein
• Pdcd-1 is a 55 KD receptor protein related to CD28/CTLA4 co-stimulatory/inhibitory receptor family ⁇ Blank et al, 2005 Cancer Immunol Immunother 54:307-314).
• the full length PD-1 contains 288 amino acid residues (NCBI accession number: NP 005009).
• TILs tumor-infiltrating lymphocytes
• PD-1 ligand expression in tumor cells were reported in varieties of cancers involved in different types of tissues and organs such as lung (Konishi et al, 2004 Clin Cancer Res 10:5094-5100), liver ⁇ Shi et al, 2008 Int J Cancer 128:887-896; Gao et al, 2009 Clin Cancer Res 15:971- 979), stomach (Wu et al, 2006 Acta Histochem 108: 19-24), kidney (Thompson et al, 2004 Proc Natl Acad Sci 101 : 17174-17179; Thompson et al, 2007 Clin Cancer Res 13: 1757-1761), breast (Ghebeh et al, 2006 Neoplasia 8: 190-198), ovary (Hamanishi et al.
• WO 2013/097224 Al disclosed a second generation B-RAF inhibitor, which has
• PCT application PCT/CN2016/079251 discloses pharmaceutically-acceptable salt of the second generation B-RAF inhibitors in WO 2013/097224 Al, particularly, 5-(((lR,laS,6bR)-l-(6- (trifluoromethyl)-lH-benzo[d]imidazol-2-yl)-la,6b-dihydro-lH-cyclopropa[b]benzofuran-5- yl)oxy)-3,4-dihydro-l,8-naphthyrdin-2(lH)-one Sesqui-Maleate (hereinafter Compound 1) for the treatment of cancers with aberrations in the RAF-MEK-ERK MAPK pathway including B-Raf mutations, K-Ras/N-Ras mutations and NF1 mutations, which has potent and reversible inhibitory activities against RAF family kinase -Raf and B-Raf V600E .
• WO 2015/035606 Al disclosed a monoclonal antibody comprising a heavy chain variable region (Vh) and a light chain variable region (Vk) (comprising SEQ ID No 24 and SEQ ID No 26, respectively) and a IgG4 heavy chain effector or constant domain (comprising SEQ ID NOs: 88), hereinafter Mab 1, which specifically binds to PD-1, especially PD-1 residues including K45 and 193; or, 193, L95 and P97, and inhibits PD-l-medidated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding.
• Vh heavy chain variable region
• Vk light chain variable region
• IgG4 heavy chain effector or constant domain comprising SEQ ID NOs: 88
• the inventors of the present application have found that the combination of the above Anti- PD1 Antibodies (i.e., Mab 1) and antibody fragments thereof with the selective B-Raf inhibitor (i.e., Compound 1) surprisingly and unexpectedly augments T cell responses in a subject suffering from cancer associated with K-Ras mutations by enhancing IFN- ⁇ production.
• the selective B-Raf inhibitor i.e., Compound 1
• the inventors of the present application have unexpectedly found that the combination of the particular Anti-PDl Antibodies (i.e., Mab 1) and the particular selective B-Raf inhibitor (i.e., Compound 1) resulted in synergistic inhibition of tumor growth in cancers associated with K-Ras mutations as compared with the monotherapy of the Anti-PDl Antibodies or the B-Raf inhibitor alone.
• the particular Anti-PDl Antibodies i.e., Mab 1
• the particular selective B-Raf inhibitor i.e., Compound 1
• a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer comprising a humanized antagonist monoclonal antibody against PD-1 and a RAF inhibitor.
• the pharmaceutical combination produces synergistic efficacy in inhibiting tumor growth in cancer.
• a method for the prevention, delay of progression or treatment of cancer in a subject comprising administering to the subject in need thereof a
• a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.
• a humanized antagonist monoclonal antibody against PD-1 for use in the prevention, delay of progression or treatment of cancer in combination with a RAF inhibitor.
• a RAF inhibitor for use in the prevention, delay of progression or treatment of cancer in combination with a humanized antagonist monoclonal antibody against PD-1.
• a pharmaceutical combination in the manufacture of a medicament for use in the prevention, delay of progression or treatment of cancer, said pharmaceutical combination comprising a humanized antagonist monoclonal antibody against PD-1 and a RAF inhibitor.
• an article of manufacture, or "kit” comprising a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising a PD-1 antagonist, the second container comprises at least one dose of a medicament comprising a RAF inhibitor, and the package insert comprises instructions for treating cancer a subject using the medicaments.
• Figure 1 shows the level of IFN- ⁇ produced from activated PBMC in tumor
• spheriod/PBMC co-culture system after treatment with RAF inhibitor alone or combination of RAF inhibitor and anti-PD-1 mAb.
• Figure 2 shows the combination effect of RAF inhibitor and anti-PD-1 mAb on tumor growth in Calu-6 xenograft model in the presence of human PBMCs.
• Figure 3 shows the combination effect of RAF inhibitor and anti-PD-1 mAb on tumor growth in human primary colon cancer BCCO-028 xenograft model in the presence of human PBMCs.
• Figure 4 shows an X-ray diffraction pattern of Compound 1 in a crystalline form
• Figure 5 shows a 1 H-NMR spectrum of the crystalline form of Compound 1.
• Figure 6 shows a C- MR spectrum of the crystalline form of Compound 1.
• TILs Tumor-infiltrating lymphocytes
• a molar ratio (free base/maleic acid, n) of about 1 may vary between 0.8 and 1.2.
• alkyl herein means a monoradical branched or linear saturated hydrocarbon chain comprising from 1 to 18, such as from 1 to 12, further such as from 1 to 6, carbon atoms.
• Alkyl groups include, but not limited to, methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, t- butyl, n-hexyl, n-decyl, tetradecyl, and the like.
• alkynyl herein means a monoradical branched or linear unsaturated hydrocarbon group comprising at least one C ⁇ C triple bond and from 2 to 18, such as from 2 to 8, further such as from 2 to 6 carbon atoms.
• Alkynyl groups include, but not limited to, ethynyl (-C ⁇ CH), propargyl (or propynyl, i.e. -C ⁇ CCH 3 ), and the like.
• cycloalkyl herein means a cyclic alkyl group comprising from 3 to 20 carbon atoms, or from 3 to 10 carbon atoms, or from 3 to 8 carbon atoms or from 3 to 6 carbon atoms having a monocyclic ring or multiple condensed rings.
• a cycloalkyl group may be saturated and partially unsaturated.
• monocyclic saturated cycloalkyl groups include, but not limited to, C 3-8 cycloalkyl selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
• Examples of monocyclic partially unsaturated cycloalkyl groups include, but not limited to, cyclopent-l-enyl, l-cyclopent-2-enyl, l-cyclopent-3-enyl, 1- cyclohex-l-enyl, l-cyclohex-2-enyl, l-cyclohex-3-enyl, and cyclohexadienyl.
• aryl herein means a monovalent aromatic hydrocarbon radical comprising from 6 to 20 carbon atoms, such as from 6 to 10 carbon atoms derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
• Aryl includes bicyclic radicals comprising an aromatic ring fused to a saturated, partially unsaturated ring, or aromatic carbocyclic or heterocyclic ring.
• aryl groups include, but not limited to, radicals derived from benzene (phenyl), substituted benzenes, naphthalene, anthracene, biphenyl, indenyl, indanyl, 1,2- dihydronapthalene, 1,2,3,4-tetrahydronapthyl, and the like.
• halogen or "halo" herein means F, CI, Br or I.
• heteroaryl herein means a group selected from:
• 5- to 7-membered aromatic, monocyclic rings comprising at least one heteroatom, for example, from 1 to 4, or, in some embodiments, from 1 to 3, heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon;
• 8- to 12-membered bicyclic rings comprising at least one heteroatom, for example, from 1 to 4, or, in some embodiments, from 1 to 3, or, in other embodiments, 1 or 2, heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring; and
• 11- to 14-membered tricyclic rings comprising at least one heteroatom, for example, from 1 to 4, or in some embodiments, from 1 to 3, or, in other embodiments, 1 or 2, heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in an aromatic ring.
• the heteroaryl group includes a 5- to 7-membered heterocyclic aromatic ring fused to a 5- to 7-membered cycloalkyl ring.
• the point of attachment may be at the heteroaromatic ring or at the cycloalkyl ring.
• the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is not more than 1.
• heteroaryl group examples include, but not limited to, (as numbered from the linkage position assigned priority 1) pyridyl (such as 2-pyridyl, 3-pyridyl, or 4-pyridyl), cinnolinyl, pyrazinyl, 2,4-pyrimidinyl, 3,5-pyrimidinyl, 2,4-imidazolyl, imidazopyridinyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, thienyl, triazinyl, benzothienyl, furyl, benzofuryl, benzoimidazolyl, indolyl, isoindolyl, indolinyl, phthalazinyl, pyrazinyl, pyridazinyl, pyrrolyl, triazolyl, quinolinyl, isoquinolin
• quinoxalinyl naphthyridinyl, furopyridinyl, benzothiazolyl (such as benzo[d]thiazol-6-yl), indazolyl (such as lH-indazol-5-yl) and 5,6,7,8-tetrahydroisoquinoline.
• heterocyclic or “heterocycle” or “heterocyclyl” herein means a ring selected from 4- to 12-membered monocyclic, bicyclic and tricyclic, saturated and partially unsaturated rings comprising at least one carbon atoms in addition to at least one heteroatom, such as from 1-4 heteroatoms, further such as from 1-3, or further such as 1 or 2 heteroatoms, selected from oxygen, sulfur, and nitrogen.
• Heterocycle herein also means a 5- to 7-membered heterocyclic ring comprising at least one heteroatom selected from N, O, and S fused with 5-, 6-, and /or 7-membered cycloalkyl, carbocyclic aromatic or heteroaromatic ring, provided that the point of attachment is at the heterocyclic ring when the heterocyclic ring is fused with a carbocyclic aromatic or a
• Heterocycle herein also means an aliphatic spirocyclic ring comprising at least one heteroatom selected from N, O, and S, provided that the point of attachment is at the heterocyclic ring.
• the rings may be saturated or have at least one double bond (i.e., partially unsaturated).
• the heterocycle may be substituted with oxo.
• the point of the attachment may be carbon or heteroatom in the heterocyclic ring.
• a heterocycle is not a heteroaryl as defined herein.
• heterocycle examples include, but not limited to, (as numbered from the linkage position assigned priority 1) 1-pyrrolidinyl, 2-pyrrolidinyl, 2,4-imidazolidinyl, 2,3-pyrazolidinyl, 1- piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2,5-piperazinyl, pyranyl, 2-morpholinyl, 3- morpholinyl, oxiranyl, aziridinyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, 1,2-dithietanyl, 1,3- dithietanyl, dihydropyridinyl, tetrahydropyridinyl, thiomorpholinyl, thioxanyl, piperazinyl, homopiperazinyl, homopiperidinyl, azepanyl, oxepanyl,
• a substituted heterocycle also includes a ring system substituted with one or more oxo moieties, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-l- thiomorpholinyl and 1,1-dioxo-l-thiomorpholinyl.
• oxo moieties such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-l- thiomorpholinyl and 1,1-dioxo-l-thiomorpholinyl.
• fused ring herein means a polycyclic ring system, e.g., a bicyclic or tricyclic ring system, in whcih two rings share only two ring atoms and one bond in common.
• fused rings may comprise a fused bicyclic cycloalkyl ring such as those having from 7 to 12 ring atoms arranged as a bicyclic ring selected from [4,4], [4,5], [5,5], [5,6] and [6,6] ring systems as mentioned above; a fused bicylclic aryl ring such as 7 to 12 membered bicyclic aryl ring systems as mentioned above, a fused tricyclic aryl ring such as 10 to 15 membered tricyclic aryl ring systems mentioned above; a fused bicyclic heteroaryl ring such as 8- to 12-membered bicyclic heteroaryl rings as mentioned above, a fused tricyclic heteroaryl ring such as 11- to 14-membered tricyclic heteroaryl rings as mentioned above; and a fused bicyclic or tricyclic heterocyclyl ring as mentioned above.
• a fused bicyclic cycloalkyl ring such as those having from 7 to 12 ring
• administration when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid, mean contact of an exogenous pharmaceutical, therapeutic, diagnostic agent, or composition to the animal, human, subject, cell, tissue, organ, or biological fluid.
• Treatment of a cell encompasses contact of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell.
• administration and “treatment” also means in vitro and ex vivo treatments, e.g., of a cell, by a reagent, diagnostic, binding compound, or by another cell.
• subject herein includes any organism, preferably an animal, more preferably a mammal (e.g., rat, mouse, dog, cat, rabbit) and most preferably a human.
• pharmaceutically acceptable salt herein includes, but not limited to salts with inorganic acids, selected, for example, from hydrochl orates, phosphates, diphosphates,
• hydrobromates sulfates, sulfinates, and nitrates; as well as salts with organic acids, selected, for example, from malates, maleates, fumarates, tartrates, succinates, citrates, lactates,
• methanesulfonates p- toluenesulfonates, 2-hydroxy ethyl sulfonates, benzoates, salicylates, stearates, alkanoates such as acetate, and salts with HOOC-(CH 2 ) n -COOH, wherein n is selected from 0 to 4.
• examples of pharmaceutically acceptable cations include, but not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium.
• antibody herein is used in the broadest sense and specifically covers antibodies (including full length monoclonal antibodies) and antibody fragments so long as they recognize PD- 1.
• An antibody molecule is usually monospecific, but may also be described as idiospecific, heterospecific, or polyspecific.
• Antibody molecules bind by means of specific binding sites to specific antigenic determinants or epitopes on antigens.
• Antibody fragments comprise a portion of a full length antibody, generally the antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab') 2 , and Fv fragments; diabodies; linear antibodies;
• single-chain antibody molecules and multispecific antibodies formed from antibody fragments.
• the term "monoclonal antibody” or “mAb” or “Mab” herein means a population of substantially homogeneous antibodies, i.e., the antibody molecules comprised in the population are identical in amino acid sequence except for possible naturally occurring mutations that may be present in minor amounts.
• conventional (polyclonal) antibody preparations typically include a multitude of different antibodies having different amino acid sequences in their variable domains, particularly their CDRs, which are often specific for different epitopes.
• the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
• Monoclonal antibodies may be obtained by methods known to those skilled in the art. See, for example Kohler et al (1975); U.S. Pat. No. 4,376, 110; Ausubel et al (1987- 1999); Harlow et al (1988); and Colligan et al (1993).
• the mAbs disclosed herein may be of any immunoglobulin class including IgG, IgM, IgD, IgE, IgA, and any subclass thereof.
• a hybridoma producing a mAb may be cultivated in vitro or in vivo.
• High titers of mAbs can be obtained in in vivo production where cells from the individual hybridomas are injected intraperitoneally into mice, such as pristine-primed Balb/c mice to produce ascites fluid containing high concentrations of the desired mAbs.
• MAbs of isotype IgM or IgG may be purified from such ascites fluids, or from culture supernatants, using column chromatography methods well known to those of skill in the art.
• the basic antibody structural unit comprises a tetramer.
• Each tetramer includes two identical pairs of polypeptide chains, each pair having one "light chain” (about 25 kDa) and one "heavy chain” (about 50-70 kDa).
• the amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
• the carboxy -terminal portion of the heavy chain may define a constant region primarily responsible for effector function.
• human light chains are classified as kappa and lambda light chains.
• human heavy chains are typically classified as ⁇ , ⁇ , ⁇ , ⁇ , or ⁇ , and define the antibody's isotypes as IgA, IgD, IgE, IgG, and IgM, respectively.
• the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids.
• variable regions of each light/heavy chain (Vk/Vh) pair form the antibody binding site.
• an intact antibody has two binding sites.
• the two binding sites are, in general, the same.
• variable domains of both the heavy and light chains comprise three hypervariable regions, also called “complementarity determining regions (CDRs)", which are located within relatively conserved framework regions (FR).
• CDRs complementarity determining regions
• FR framework regions
• the CDRs are usually aligned by the framework regions, enabling binding to a specific epitope.
• both light and heavy chains variable domains comprise FR-1, CDR-1, FR-2, CDR-2, FR-3, CDR-3, and FR-4.
• the assignment of amino acids to each domain is, generally, in accordance with the definitions of Sequences of Proteins of Immunological Interest, Kabat, et al. National Institutes of Health, Bethesda, Md. ; 5 ⁇ m> ed; NIHPubl. No. 91-3242 (1991); Kabat (1978) Adv. Prot.
• hypervariable region means the amino acid residues of an antibody that are responsible for antigen-binding.
• the hypervariable region comprises amino acid residues from a "complementarity determining region” or "CDR" (i.e., CDR-L1, CDR-L2 and CDR-L3 in the light chain variable domain and CDR-H1, CDR-H2 and CDR-H3 in the heavy chain variable domain).
• CDR complementarity determining region
• antibody fragment or "antigen binding fragment” means antigen binding fragments of antibodies, i.e. antibody fragments that retain the ability to bind specifically to the antigen bound by the full-length antibody, e.g. fragments that retain one or more CDR regions.
• antibody binding fragments include, but not limited to, Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules, e.g., sc-Fv; nanobodies and multispecific antibodies formed from antibody fragments.
• An antibody that "specifically binds to" a specified target protein is an antibody that exhibits preferential binding to that target as compared to other proteins, but this specificity does not require absolute binding specificity.
• An antibody is considered “specific” for its intended target if its binding is determinative of the presence of the target protein in a sample, e.g. without producing undesired results such as false positives.
• Antibodies, or binding fragments thereof, useful in the present invention will bind to the target protein with an affinity that is at least two fold greater, preferably at least ten times greater, more preferably at least 20- times greater, and most preferably at least 100-times greater than the affinity with non-target proteins.
• An antibody herein is said to bind specifically to a polypeptide comprising a given amino acid sequence, e.g. the amino acid sequence of a mature human PD-1 molecule, if it binds to polypeptides comprising that sequence but does not bind to proteins lacking that sequence.
• human antibody herein means an antibody that comprises human
• a human antibody may contain murine carbohydrate chains if produced in a mouse, in a mouse cell, or in a hybridoma derived from a mouse cell.
• humanized antibody means forms of antibodies that contain sequences from non-human (e.g., murine) antibodies as well as human antibodies. Such antibodies contain minimal sequence derived from non-human immunoglobulin.
• the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence.
• the humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
• Fc immunoglobulin constant region
• the prefix "hum”, "hu” or “h” is added to antibody clone designations when necessary to distinguish humanized antibodies from parental rodent antibodies.
• the humanized forms of rodent antibodies will generally comprise the same CDR sequences of the parental rodent antibodies, although certain amino acid substitutions may be included to increase affinity, increase stability of the humanized antibody, or for other reasons.
• cancer or tumor mean or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
• examples of cancer include but not limited to, adrenal cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer (including small- cell lung cancer, or non-small cell lung cancer), lymphoma, melanoma, ovarian cancer, pancreatic cancer, skin cancer, or thyroid tumors and their complications.
• Particularly preferred cancers or tumors that may be treated by the combination disclosed herein include those characterized by B-Raf mutations, K-Ras/N-Ras mutations and/or NF1 mutations.
• the most preferred cancers or tumors that may be treated by the combination disclosed herein include non-small cell lung cancer, colorectal cancer, and endometrial cancer, each of which is associated with K-Ras mutations.
• CDRs means complementarity determining region(s) in an immunoglobulin variable region, defined using the Kabat numbering system, unless otherwise indicated.
• PD-1 antagonist means any chemical compound or biological molecule that blocks binding of PD-Ll expressed on a cancer cell to PD-1 expressed on an immune cell (T cell, B cell or KT cell) and preferably also blocks binding of PD-L2 expressed on a cancer cell to the immune- cell expressed PD-1.
• Alternative names or synonyms for PD-1 and its ligands include: PDCD1, PD1, CD279 and SLEB2 for PD-1 ; PDCD1L1, PDL-1, B7H1, B7-4, CD274 and B7-H for PD-Ll ; and PDCD1L2, PDL2, B7-DC, Btdc and CD273 for PD-L2.
• the PD-1 antagonist is an antibody or a fragment antigen binding thereof, which specifically binds to human PD-1.
• the PD-1 antagonist is an antibody which comprises a heavy chain variable region (Vh) and a light chain variable region (Vk) that contain com lement determinant re ions CDRs listed as follows:
• the PD-1 antagonist is an antibody which comprises a heavy chain variable region (Vh) and a light chain variable region (Vk) that contain any combinations of CDRs listed as follows:
• the PD-1 antagonist is an antibody which comprises a heavy chain variable region (Vh) and a light chain variable region (Vk) comprising: a) mu317 (SEQ ID NOs: 4 and 6, respectively); p) 317-3H1 (SEQ ID NOs: 69 and 26, respectively); b) mu326 (SEQ ID NOs: 8 and 10. respectively); q) 317-311 (SEQ ID NOs: 70 and 26. respectively);
• m) 317-3E1 (SEQ ID NOs: 66 and 26, respectively); aa) 326-3B N55D (SEQ ID NOs: 80 and 30, respectively); n) 317-3F1 (SEQ ID NOs: 67 and 26, respectively); ab) 326-4A1 (SEQ ID NOs: 28 and 81, respectively); or o) 317-3G1 (SEQ ID NOs: 68 and 26, respectively); ac) 326-4A2 (SEQ ID NOs: 28 and 82. respectively).
• the PD-1 antagonist is an antibody which comprises a IgG4 heavy chain effector or constant domain comprising any of SEQ ID NOs: 83-88.
• the PD-1 antagonist is an antibody which contains a F(ab) or F(ab) 2 comprising a domain said above, including a heavy chain variable region (Vh), a light chain variable region (Vk) and a IgG4 heavy chain effector or constant domain .
• the PD-1 antagonist is an antibody which comprise a heavy chain variable region (Vh) and a light chain variable region (Vk), and a IgG4 heavy chain effector or constant domain comprising SEQ ID NOs: 87 or 88, wherein the heavy chain variable region (Vh) and the light chain variable region (Vk) comprise:
• mu317 SEQ ID NOs: 4 and 6, respectively
• p 317-3H1
• mu326 SEQ ID NOs: 8 and 10, respectively
• q 317-311
• 317-4B6 SEQ ID NOs: 24 and 26, respectively
• m) 317-3E1 (SEQ ID NOs: 66 and 26, respectively); aa) 326-3B N55D (SEQ ID NOs: 80 and 30, respectively); n) 317-3F1 (SEQ ID NOs: 67 and 26, respectively); ab) 326-4A1 (SEQ ID NOs: 28 and 81, respectively); or o) 317-3G1 (SEQ ID NOs: 68 and 26, respectively); ac) 326-4A2 (SEQ ID NOs: 28 and 82, respectively).
• the PD-1 antagonist is an antibody which comprises a heavy chain variable region (Vh) and a light chain variable region (Vk), and an IgG4 heavy chain effector or constant domain comprising SEQ ID NO: 88, wherein the heavy chain variable region (Vh) and the light chain variable region (Vk) comprises SEQ ID NO: 24 and SEQ ID NO: 26, respectively.
• Anti-PDl Antibodies and antibody fragments thereof disclosed herein may be prepared in accordance with the disclosure of WO 2015/035606 Al, the entire disclosure of which is expressly incorporated herein by reference.
• RAF inhibitor means a compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
• the RAF inhibitor is a compound of Formula
• X is selected from CH 2 and O;
• R 13 , R 14 and R 15 which may be the same or different, are each selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or (R 13 and R 14) , and /or (R 14 and R 15 ) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent R 16 ;
• the compound of Formula (I) is optically pure.
• X in Formula (I) is O.
• X in Formula (I) is CH 2 .
• R 8 , R 9 , R 10 , and R 11 in Formula (I), which may be the same or different, are each independently selected from alkyl (e.g., methyl, tert-butyl), hydrogen, haloalkyl (e.g., -CF 3 ), halogen, hydroxy, -CN, -Oalkyl (e.g., methoxy), -Ohaloalkyl (e.g., OCF 3 ), and aryl (e.g., phenyl).
• the RAF inhibitor is a compound of Formula
• X is selected from CH 2 and O;
• R 8 , R 9 , R 10 and R 11 which may be the same or different, are each selected from hydrogen, halogen, alkyl, -CN, cycloalkyl, aryl, heterocyclyl, -OR 13 , -CONR 13 R 14 , wherein the alkyl, and aryl are each optionally substituted with at least one substituent R 16 , or (R 8 and R 9 ), and /or (R 9 and R 10 ), and /or (R 10 and R 11 ) together with the ring to which they are attached, form a fused ring selected from cycloalkyl;
• R 13 , and R 14 which may be the same or different, are each selected from H, alkyl, and haloaklyl;
• R 16 is selected from halogen, haloalkyl, and alkyl.
• the RAF inhibitor is a compound of Formula
• X is selected from CH 2 and O;
• R 8 is selected from H, F, CI, and Br;
• R 9 is selected from H, F, CI, Br , and
• R 10 is selected from H, F, CI, Br, OH, -CN, Ci -6 alkyl, CF 3 , phenyl, OCi -6 alkyl, OCi.
• R 13 and R 14 are each selected
• R 11 is selected from H, F, CI, Br, and CF 3 ;
• the RAF inhibitor is a compound of selected from the following compounds:
• the RAF inhibitor is a compound of selected from th
• the RAF inhibitor is a compound of selected from
• the RAF inhibitor is a compound of Formula
• the RAF inhibitor is a maleate salt of the compound of Formula (II).
• the RAF inhibitor is a compound of Formula
• n is a number from about 0.5 to about 1.5.
• the RAF inhibitor is a compound of Formula (Ilia)— i.e., Compound 1
• the RAF inhibitor disclosed herein such as the compound of Formula (I), may be synthesized by synthetic routes disclosed in WO 2013/097224 Al, the entire disclosure of which is expressly incorporated herein by reference.
• the RAF inhibitor, i.e., Compound 1, disclosed herein may be prepared in accordance with the procedures in PCT/CN2016/079251, the entire disclosure of which is expressly incorporated herein by reference.
• the combination therapy may be administered as a simultaneous, or separate or sequential regimen.
• the combination may be administered in two or more administrations.
• the combined administration includes coadministration, using separate
• the pharmaceutically acceptable salt thereof can be administered for a time period of about 1 to about 10 days after administration of the PD-1 antagonist. In another embodiment of each of the above five aspects, the RAF inhibitor or the pharmaceutically acceptable salt thereof can be administered for a time period of about 1 to 10 days before administration of the combination begins. In another embodiment of each of the above five aspects, administration of the RAF inhibitor or the
• Suitable dosages for any of the above coadministered agents are those presently used and may be lowered due to the combined action (synergy) of the RAF inhibitor and the PD-1 antagonist, such as to increase the therapeutic index or mitigate toxicity or other side-effects or consequences.
• the RAF inhibitor and the PD-1 antagonist may be further combined with surgical therapy and radiotherapy.
• the amounts of the RAF inhibitor and the PD-1 antagonist disclosed herein and the relative timings of administration be determined by the individual needs of the patient to be treated, administration route, severity of disease or illness, dosing schedule, as well as evaluation and judgment of the designated doctor.
• the administered dosage of the RAF inhibitor is 1-100 mg/ day (in terms of the parent compound), and the administration frequency is one to three times a day; preferably, the administered dosage of the RAF inhibitor is 5-80 mg/ day (in terms of the parent compound), and the administration frequency is one to three times a day; more preferably, the administered dosage of the RAF inhibitor is 10-40 mg/ day (in terms of the parent compound), and the administration frequency is one time a day.
• the preferred range of the effective dosage of the RAF inhibitor disclosed herein may be approximately 0.01-10 mg daily per kilogram of body weight; or more preferably 0.1-1 mg per day per kilo gram of body weight in single or separate doses.
• the RAF inhibitor is administrated at a dose of 5-80 mg once daily.
• the PD-1 antagonist is administered at a dose of 0.5-30 mg/kg, such as 0.5-20 mg/kg, further such as 0.5-10 mg/kg once weekly, or every two weeks, or every three weeks , or every four weeks.
• the RAF inhibitor and the PD-1 antagonist disclosed herein may be administered in various known manners, such as orally, topically, rectally, parenterally, by inhalation spray, or via an implanted reservoir, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
• parenteral as used herein includes subcutaneous, intracutaneous, intravenous,
• the RAF inhibitor and the PD-1 antagonist disclosed herein may be administered in different route.
• the RAF inhibitor is administered orally
• the PD-1 antagonist is administered parenterally such as subcutaneously, intracutaneously, intravenously or intraperitoneally.
• the PD-1 antagonist is an antibody which comprises a heavy chain variable region (Vh) and a light chain variable region (Vk), and a IgG4 heavy chain effector or constant domain comprising SEQ ID NO: 88, wherein the heavy chain variable region (Vh) and the light chain variable region (Vk) comprise SEQ ID NO: 24 and SEQ ID NO: 26, respectively; and the RAF inhibitor is the compound of Formula (Ilia) disclosed herein.
• the PD-1 antagonist Mab-1 is administrated to a subject at a dose of 0.5-10 mg/kg i.v. or i.p. QW or Q2W or Q3W, and the RAF inhibitor Compound 1 is administrated to a subject at a dose of 5-80 mg QD.
• the PD-1 antagonist Mab-1 is administrated to a subject at a dose of 0.5-10 mg/kg i.v. or i.p. QW or Q2W or Q3W, and the RAF inhibitor Compound 1 is administrated to a subject at a dose of 10-30 mg QD.
• the PD-1 antagonist Mab-1 is administrated parenterally such as subcutaneously, intracutaneously, intravenously or
• the pharmaceutical combination produces synergistic efficacy in inhibiting tumor growth in cancer, such as adrenal cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer (including small- cell lung cancer, or non-small cell lung cancer), lymphoma, melanoma, ovarian cancer, pancreatic cancer, skin cancer, or thyroid tumors and their complications.
• cancer such as adrenal cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer (including small- cell lung cancer, or non-small cell lung cancer), lymphoma, melanoma, ovarian cancer, pancreatic cancer, skin cancer, or thyroid tumors and their complications.
• cancer such as adrenal cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, head and neck cancer, kidney cancer, liver cancer,
• the most preferred cancers or tumors that may be treated by the combination disclosed herein include non-small cell lung cancer, colorectal cancer, and endometrial cancer, each of which is associated with K-Ras mutations.
• the combination is useful in a method for the prevention, delay of progression or treatment of cancer.
• IPA 83 kg was added to the residue of Step 9.
• Maleic acid (5 kg) in water (29 kg) was added into the mixture and stirred for 4 hours at about 50°C, then cooled to 35°C and stirred for 12 hours at that temperature.
• Compound 1 was identified as a crystalline form by powder X-ray diffraction pattern method as shown in Figure 4. 1H-NMR spectra for Compound 1
• HEK-293-OS8-PD-L1 cells and Sk-Mel-28 cells (B-Raf V600E ) were mixed at 1 : 1 ratio at a density of 5 x 10 4 cells/mL in ice-cold medium.
• the Matrigel ® Matrix (Corning) was added to the cell suspension at a final concentration of 2% to assist the formation of three-dimensional structures.
• Cells were plated into ULA 96-well round-bottomed plates (Corning) and grow for three days to form tumor spheroids.
• PBMCs Blood samples from healthy donors were collected in heparinized tubes and PBMCs were isolated using Fioll-Paque PLUS reagent (GE Healthcare) according to the instruction of manufacturer. Prior to co-culture with tumor spheroids, PBMCs were activated with 1 ⁇ g/mL anti-CD3 antibody for two days.
• Co-culture was performed in ULA 96-well round-bottomed plates containing one tumor spheroid and 10 4 PBMCs/well in the present of a series dilution of Compound 1 (5-(((lR, laS,6bR)-l-(6-(trifluoromethyl)-lH- benzo[d]imidazol-2-yl)-la,6b-dihydro-lH-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-l,8- naphthyrdin-2(lH)-one Sesqui-Maleate) combining with Mab 1 (containing a heavy chain variable region (Vh) as shown in SEQ ID NO: 24, a light chain variable region (Vk) as shown in SEQ ID NO: 26, and a IgG4 heavy chain effector or constant domain comprising SEQ ID NO: 88) for three days.
• IFN- ⁇ production level in culture supernatant was determined
• Compound 1 alone promoted IFN- ⁇ releasing from PBMCs in co-culture system at concentration between 10 nM and 100 nM, and suppressed IFN- ⁇ releasing at high concentrations (> 3 ⁇ ).
• Combination of intermediate level Compound 1 and Mab 1 showed significantly enhanced PBMC IFN- ⁇ production, indicating better in vitro T cell activity (Figure 1).
• EXAMPLE 2 Effect of the combination of anti-PD-1 mAb and RAF inhibitor in a K-Ras mutation lung cancer and B-Raf V600E mutation Colon cancer models in the presence of in the presence of human PBMCs
• PBMCs peripheral blood mononuclear cells
• NOD/SCID mice were pre-treated with cyclophosphamide (prepared in saline, 150 mg/kg, i.p.) and disulfiram (prepared in 0.8% Tween-80 in saline, 125 mg/kg, p.o., one hour after each dose of cyclophosphamide) once daily for two days. Animals were then injected with tumor cells or tumor fragments and PBMCs mixture 24 hours after the second dose of cyclophosphamide.
• cyclophosphamide prepared in saline, 150 mg/kg, i.p.
• disulfiram prepared in 0.8% Tween-80 in saline, 125 mg/kg, p.o., one hour after each dose of cyclophosphamide
• DMEM Dulbecco minimum essential medium
• fetal bovine serum 10% (v/v) fetal bovine serum, and 100 ⁇ g/ml of penicillin and streptomycin .
• culture medium was replaced with fresh medium.
• media was removed and cells were collected as described above, except that cells were re-suspended in cold (4 °C) DPBS to give a final concentration of 5 x 10 7 cells/ml and placed on ice prior to inoculation.
• each mouse was cleaned with 70%) ethanol prior to cell inoculation.
• Each animal was injected subcutaneously with 5 ⁇ 10 6 Calu-6 cells and 2.5 ⁇ 10 6 PBMC (200 ⁇ cell mixture in 50% matrigel) in the right front flank via a 26- gauge needle.
• BCCO-028 is derived from tumor tissues surgically removed from a patient with colon cancer. Within 2 to 4 hours following patient surgery, the tumor samples were subcutaneously engrafted into the scapular area of anesthetized NOD/SCID mice. After tumors grew to around 300-1000 mm 3 , tumors were surgically removed and fragments were passaged in NOD/SCID mice by subsequent engraftments. Animals were then implanted with BCCO-028 tumor fragments and PBMCs 24 hours after the second dose of cyclophosphamide.
• each NOD/SCID mouse was cleaned with 70%) ethanol prior to tumor fragments inoculation.
• Each animal was implanted subcutaneously with a fragment (around 3 x3 x3 mm 3 ) of BCCO-028 colon cancer (passage 5) in the right flank via 14-gauge trocar needle, followed by subcutaneously injection of 5 x l0 6 PBMC in 200 ⁇ of 50% matrigel near the edge of tumor fragment via a 26-gauge needle.
• mice were randomly assigned into 4 groups with 8-1 1 mice per group.
• the groups consisted of a control group (no drug treatment), 5 mg/kg of Compound 1 (based on free-base weight), 10 mg/kg of Mab 1, and the combination of Compound 1 and Mab 1.
• Treatments were administered in a volume of 10 ml/kg body weight, assessed immediately before dosing and the volume dosed was adjusted accordingly.
• Compound 1 was administered by oral gavage (p.o.) once daily (QD) and Mab 1 was administered by intraperitoneal (i.p.) injection once weekly (QW). After implantation, primary tumor volume was measured in two dimensions using a calliper
• Tumor growth inhibition (TGI) was calculated using the following formula:
• treated t treated tumor volume at time t
• placebo t placebo tumor volume at time t

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Immunology (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Genetics & Genomics (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=60912473

Family Applications (1)

Country Status (8)

Cited By (1)

Families Citing this family (7)

Citations (3)

Family Cites Families (205)

• 2017
  • 2017-06-14 CN CN201780042321.XA patent/CN109475536B/zh active Active
  • 2017-06-14 WO PCT/IB2017/053521 patent/WO2018007885A1/en not_active Ceased
  • 2017-06-14 EP EP17823723.6A patent/EP3481393B1/en active Active
  • 2017-06-14 US US16/315,539 patent/US10864203B2/en active Active
  • 2017-06-14 AU AU2017293423A patent/AU2017293423B2/en active Active
  • 2017-06-14 JP JP2019500500A patent/JP6993056B2/ja active Active
  • 2017-06-14 NZ NZ749997A patent/NZ749997A/en unknown
  • 2017-07-05 TW TW106122543A patent/TWI755406B/zh active
• 2020
  • 2020-11-16 US US17/099,115 patent/US11534431B2/en active Active

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events